Vaxcyte, Inc. (PCVX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$61.92-5.72%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PCVX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 1,093.0 | 794.3 | 476.6 | 332.3 | 169.5 | 78.4 | 73.6 |
| Operating Income | (1,231.2) | (923.7) | (569.5) | (468.0) | (232.3) | (103.7) | (89.6) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest & Investment Income | 102.0 | 119.7 | 110.0 | 62.9 | 8.4 | 0.3 | 0.2 |
| Net Interest Expenses | — | — | — | (62.9) | (8.4) | (0.3) | (0.2) |
| Other Non-Operating Income / Expenses | 82.7 | 157.0 | — | 65.8 | — | — | — |
| Asset Writedown | — | — | 0.0 | 0.0 | 0.2 | 0.0 | 0.3 |
| Income Tax Expense | — | — | — | 0.0 | — | — | — |
| Net Income | |||||||
| Net Income | (382.6) | (766.6) | (463.9) | (0.4) | (0.2) | (0.1) | (89.2) |
| Per Share | |||||||
| Basic EPS | (2.57) | (5.63) | (3.80) | (4.14) | (3.44) | (1.93) | (3.02) |
| Diluted EPS | (2.57) | (5.63) | (3.80) | (4.14) | (3.44) | (1.93) | (3.02) |
| Dividend per Share | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Avg Shares | 148.9 | 136.1 | 122.0 | 97.2 | 64.9 | 51.9 | 29.5 |
| Diluted Weighted Avg Shares | 148.9 | 136.1 | 122.0 | 97.2 | 64.9 | 51.9 | 29.5 |
| Supplemental | |||||||
| EBITDA | — | (907.3) | (562.5) | (464.8) | (229.7) | (101.9) | (88.2) |
| EBIT | (1,231.2) | (923.7) | (569.5) | (468.0) | (232.3) | (103.7) | (89.6) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.